MetaTrader
  • Markets
  • Charts & Ideas
  • Algo
  • Noticias
  • Store
  • Corredores
  • Descargar
  • Calendario económico
  • Señales Comerciales
  • WebTerminal
  • English English
  • Русский Русский
  • 中文 中文
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Français Français
  • Italiano Italiano
  • Türkçe Türkçe
Arcus Biosciences, Inc.

RCUS

#1597
Arcus Biosciences, Inc.
20.38
+4.57%
Sector:
Básica:
Profit Currency:
Rango diario
20.07
20.44
Rango anual
6.50
26.40
Cambio diario
+4.57%
Monthly Change
-12.53%
6 month change
+92.26%
Cambio anual
+96.53%
Cierres anteriores
19.49
Open
20.15
Bid
Ask
Low
20.07
High
20.44
Volumen
601
  1. Markets
  2. Acciones
  3. Atención Sanitaria
  4. RCUS
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
Value 202020212022202320242025 TTM

Noticias

Seeking Alpha Seeking Alpha
RCUS
ayer, 23:14
Arcus Biosciences, Inc. 2025 Q4 - Results - Earnings Call Presentation (NYSE:RCUS) 2026-02-27
Zacks Zacks
ANIP RCKT RCUS CSTL
ayer, 17:46
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
Zacks Zacks
TGTX ANIP RCUS CSTL
ayer, 17:08
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
Zacks Zacks
REGN NTLA RCUS CSTL
ayer, 16:14
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Zacks Zacks
ALKS ADMA RCUS CSTL
anteayer, 16:40
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change
Zacks Zacks
ADMA RCUS MIRM CSTL
anteayer, 15:50
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
Seeking Alpha Seeking Alpha
RCUS
anteayer, 04:17
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Investing Investing
RCUS
2026.02.25
Presentación de Arcus 2025: los datos de casdatifan se fortalecen, emerge el pipeline de I&I
Investing Investing
GILD RCUS
2026.02.25
Presentación Arcus 2025: datos de casdatifan se fortalecen, emerge I&I
Investing Investing
RCUS
2026.02.25
Arcus 2025 presentation: casdatifan data strengthens, I&I pipeline emerges
Investing Investing
RCUS
2026.02.25
Arcus Biosciences earnings beat by $0.21, revenue fell short of estimates
Investing Investing
MRK AZN RCUS
2026.02.25
Arcus Biosciences en el punto de mira: resultados de ensayo renal en juego

Markets

  • Acciones
  • Divisas
  • Criptomonedas
  • Metales
  • Mercancías

Charts & Ideas

  • Ideas comerciales
  • Ideas ilustrativas
  • Gráfico

MQL5 Community

  • Market
  • Señales
  • Foro
  • Artículos
  • CodeBase

Noticias

  • Acciones
  • Divisas
  • Criptomonedas
  • Metales
  • Mercancías

Corredores

  • Todos los brókeres
  • Fórex
  • Acciones
  • Metales
MetaTrader 5
MQL5 Channels
Economic Calendar
Disclaimer and Risk Disclosure Terms of Use Información y contacto Legal
Copyright 2000-2026, MetaQuotes Ltd